Bristol Myers Squibb Company BMY
62.86
1.36
2.21%
as of 25 Sep
- Market cap
- $125.9B
- P/E
- 13.8×
Follow BMY
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years
Bristol Myers Squibb Company (BMY) Revenue
Bristol Myers Squibb Company's revenue for fiscal 2025 was $48.2B, unchanged from fiscal 2024. Over the twelve months to 30 June 2026 it was $49.2B. Over the past ten years it has ranged from $16.6B (fiscal 2015) to $48.3B (fiscal 2024); the current reading is higher than 91% of that period. Bristol Myers Squibb Company ranks 10th of 18 Drug Manufacturers General companies by revenue.
Revenue, annual
Annual
| Period | Revenue | Change |
|---|---|---|
| FY2025 | $48.2B | (0.22%) |
| FY2024 | $48.3B | 7.32% |
| FY2023 | $45.0B | (2.50%) |
| FY2022 | $46.2B | (0.49%) |
| FY2021 | $46.4B | 9.09% |
| FY2020 | $42.5B | 62.62% |
| FY2019 | $26.1B | 15.89% |
| FY2018 | $22.6B | 8.59% |
| FY2017 | $20.8B | 6.94% |
| FY2016 | $19.4B | 17.31% |
Quarterly
| Period | Revenue | Change |
|---|---|---|
| Jun 2026 | $13.0B | 12.92% |
| Mar 2026 | $11.5B | (8.10%) |
| Dec 2025 | $12.5B | 2.29% |
| Sep 2025 | $12.2B | (0.38%) |
| 42 more quarters | Free account |
Against its own ten years
Low $16.6B
High $48.3B
Ten-year median
$42.5B
Current reading's percentile
91
Revenue against peers
| Company | Revenue |
|---|---|
| PFE Pfizer Inc. compare | $63.7B |
| AZN AstraZeneca PLC compare | $61.4B |
| SNY Sanofi compare | $57.0B |
| NVS Novartis AG compare | $56.7B |
| NVO Novo Nordisk A/S compare | $51.5B |
| BMY Bristol Myers Squibb Company | $49.2B |
| GSK GSK PLC Sponsored ADR compare | $44.5B |
| AMGN Amgen Inc. compare | $38.1B |
| GILD Gilead Sciences, Inc. compare | $30.5B |
What Revenue is
Revenue tells an investor how much a company brought in from selling its goods and services over a period, before any costs are taken out.
Reported line item
More on BMY
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement